Sees FY26 adjusted EBITDA $10M to $20M
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HRTX:
- HRTX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Heron Therapeutics: Undervalued Growth Story Driven by Zynrelef and Aponvie Momentum
- Heron Therapeutics Reports Strong Preliminary Q4 2025 Revenue
- Heron Therapeutics: ZYNRELEF-Led Commercial Inflection and Undemanding Valuation Support Buy Rating and $6 Target
- Heron Therapeutics sees Q4 revenue $40.5M, consensus $39.83M